University of Pennsylvania

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1740-11-14

Employees: 5K

Market Cap: -

Website: http://www.upenn.edu

Clinical Trials

Effects of Cognitive Behavioral Therapy on Brain Serotonin Activity in People With Depression

Phase 2

Completed

Conditions: Depression

Interventions: Drug: ADAM SPECT plus No Therapy
Drug: ADAM SPECT plus Cognitive Therapy

First Posted Date: 2008-03-21

Last Posted Date: 2020-04-16

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 30

Registration Number: NCT00641108

Locations: 🇺🇸
Depression Research Unit - University of Pennsylvania, Philadelphia, Pennsylvania, United States

Efficacy of an Abstinence-Only HIV Risk-Reduction Intervention for Young African-American Adolescents

Not Applicable

Completed

Conditions: Sexually Transmitted Diseases
HIV Infections

Interventions: Behavioral: Abstinence-only HIV/STD risk-reduction intervention
Behavioral: Safer-sex-only HIV/STD risk-reduction intervention
Behavioral: Long comprehensive HIV/STD risk-reduction intervention
Behavioral: Health promotion control intervention
Behavioral: Short comprehensive HIV/STD risk-reduction intervention

First Posted Date: 2008-03-21

Last Posted Date: 2017-12-13

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 662

Registration Number: NCT00640653

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

Safety of Red Yeast Rice for High Cholesterol in Individuals With Statin Intolerance

Phase 2

Completed

Conditions: Hypercholesterolemia
Statin-Associated Myopathy

Interventions: Drug: Pravastatin
Dietary Supplement: Red Yeast Rice
Behavioral: Lifestyle modification program

First Posted Date: 2008-03-20

Last Posted Date: 2010-01-18

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 43

Registration Number: NCT00639223

Locations: 🇺🇸
Chestnut Hill Hospital, Philadelphia, Pennsylvania, United States

Evaluation of Lenalidomide (REVLIMID®) to Treat Subjects With Cutaneous Lupus Erythematosus (CLE)

Not Applicable

Completed

Conditions: Cutaneous Lupus Erythematosus (CLE)

Interventions: Drug: Lenalidomide

First Posted Date: 2008-03-12

Last Posted Date: 2023-02-09

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 5

Registration Number: NCT00633945

Locations: 🇺🇸
Hospital of the University of Pennsylvania, Department of Dermatology, Philadelphia, Pennsylvania, United States

Brain Imaging Study in Menopausal Women With and Without Major Depressive Disorder

Phase 4

Completed

Conditions: Menopause
Depression

Interventions: Drug: MDD diagnosis and Estrogen treatment
Drug: MDD diagnosis and Fluoxetine treatment
Drug: MDD diagnosis with both Estrogen and Fluoxetine treatment
Drug: No depression and estrogen treatment

First Posted Date: 2008-02-29

Last Posted Date: 2017-06-01

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 18

Registration Number: NCT00626340

Locations: 🇺🇸
Yale University, New Haven, Connecticut, United States

Testing Strategies to Improving Warfarin Adherence

Not Applicable

Completed

Conditions: Atrial Fibrillation
Deep Venous Thrombosis
Dilated Cardiomyopathies

Interventions: Behavioral: Lottery arm (Lottery and Med-eMonitor)
Behavioral: Non-Lottery (Med-eMonitor only)

First Posted Date: 2008-02-22

Last Posted Date: 2009-12-02

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 101

Registration Number: NCT00622102

Locations: 🇺🇸
Hospital of the University of Pennsylvania Anticoagulation Management Center, Philadelphia, Pennsylvania, United States

Combined Treatment for Generalized Anxiety Disorder (GAD)

Phase 2

Completed

Conditions: Generalized Anxiety Disorder

Interventions: Behavioral: Cognitive Behavioral Therapy
Drug: Venlafaxine XR

First Posted Date: 2008-02-21

Last Posted Date: 2017-02-16

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 69

Registration Number: NCT00620776

Locations: 🇺🇸
University of Pennsylvania, 3535 Market Street, Suite 650, Philadelphia, Pennsylvania, United States

Placebo Controlled Study of Atomoxetine in the Treatment of Mild to Moderate Cognitive Difficulties in Menopausal Women

Not Applicable

Completed

Conditions: Menopause
Cognitive Disturbances

Interventions: Drug: placebo
Drug: atomoxetine

First Posted Date: 2008-02-11

Last Posted Date: 2017-04-17

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 16

Registration Number: NCT00611533

Locations: 🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States

DCVax-L Vaccination With CD3/CD28 Costimulated Autologous T-Cells for Recurrent Ovarian or Primary Peritoneal Cancer

Phase 1

Withdrawn

Conditions: Primary Peritoneal Cancer
Ovarian Cancer

Interventions: Biological: DCVax-L and T Cells

First Posted Date: 2008-01-29

Last Posted Date: 2017-05-02

Lead Sponsor: University of Pennsylvania

Registration Number: NCT00603460

Locations: 🇺🇸
University of Pennsylania, Philadelphia, Pennsylvania, United States

Antidepressant Therapy in Treating Bipolar Type II Major Depression

Phase 4

Completed

Conditions: Depression
Bipolar Disorder

Interventions: Drug: Venlafaxine
Drug: Lithium Carbonate

First Posted Date: 2008-01-28

Last Posted Date: 2017-04-25

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 140

Registration Number: NCT00602537

Locations: 🇺🇸
Depression Research Unit - University of Pennsylvania, Philadelphia, Pennsylvania, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy